FindTrial
Sign In

ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00051506
Enrollment
Unknown
Registered
2003-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2006-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Neoplasms

Brief summary

The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.

Interventions

DRUGALIMTA
DRUGcarboplatin
DRUGcisplatin

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy. * Have received no prior chemotherapy for your disease. * Have at least one measurable lesion. * have an adequate performance status. * Sign an informed consent form.

Exclusion criteria

* Have previously received chemotherapy for your lung cancer. * Have been treated with a investigational drug within the last 30 days. Have previously completed or withdrawn from this study or any other study investigating ALIMTA. * Have received radiation therapy within the last 1-2 weeks. * Have brain metastasis that is uncontrolled. * Have active infection or other serious condition.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026